What is HC Wainwright’s Forecast for TYRA FY2026 Earnings?

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Investment analysts at HC Wainwright lowered their FY2026 earnings per share estimates for shares of Tyra Biosciences in a research report issued to clients and investors on Wednesday, November 11th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($2.64) for the year, down from their prior forecast of ($2.60). HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($2.69) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2026 earnings at ($0.59) EPS, Q1 2027 earnings at ($0.59) EPS, Q2 2027 earnings at ($0.61) EPS, Q3 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.62) EPS and FY2027 earnings at ($2.44) EPS.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07).

TYRA has been the topic of a number of other reports. Piper Sandler reaffirmed an “overweight” rating and issued a $56.00 target price on shares of Tyra Biosciences in a report on Tuesday, September 8th. Wedbush increased their price target on shares of Tyra Biosciences from $53.00 to $57.00 and gave the stock an “outperform” rating in a research note on Wednesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Tyra Biosciences in a research report on Thursday, September 10th. Raymond James Financial reissued a “strong-buy” rating and set a $50.00 price objective on shares of Tyra Biosciences in a research report on Tuesday, October 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $47.40.

Tyra Biosciences Price Performance

TYRA stock opened at $19.76 on Friday. The business has a 50 day simple moving average of $21.85 and a 200-day simple moving average of $29.44. Tyra Biosciences has a twelve month low of $14.67 and a twelve month high of $40.65.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of TYRA. Sterling Capital Management LLC increased its holdings in shares of Tyra Biosciences by 843.4% in the third quarter. Sterling Capital Management LLC now owns 1,217 shares of the company’s stock valued at $27,000 after purchasing an additional 1,088 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Tyra Biosciences during the third quarter worth approximately $67,000. State of Wyoming acquired a new stake in shares of Tyra Biosciences during the second quarter worth $76,000. Canada Pension Plan Investment Board acquired a new stake in shares of Tyra Biosciences during the second quarter worth $230,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Tyra Biosciences during the second quarter worth $237,000. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.